Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain

N/ACompletedNCT00195364

Wyeth is now a wholly owned subsidiary of Pfizer93 enrolled

Overview

The purpose of this study is to evaluate long-term safety of etanercept in patients with rheumatoid arthritis who successfully have completed open-label safety study 0881A1-301-EU

Study Type

OBSERVATIONAL

Enrollment

Conditions

Rheumatoid Arthritis Inflammation

Interventions

EtanerceptDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * To have completed 0881A1-301-EU study in Spain * Clinical diagnosis by ACR revised criteria of rheumatoid arthritis. Exclusion Criteria: * Hypersensibility to etanercept or any of its components * Significant concurrent medical disease

Locations (1)

Unnamed facility

Madrid, Madrid, Spain

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.